Tauvid Approval History
Tauvid (flortaucipir F 18) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Development History and FDA Approval Process for Tauvid
|May 28, 2020||FDA Approves Tauvid (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease|
|Sep 5, 2018||Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.